bristol myers

Shares of Bristol-Myers Squibb Co (NYSE: BMY) were boosted higher on Thursday after the company announced the European Commission approved its Evotaz for the treatment of HIV-1 in adults. Evotaz (atazanayir 300 mg and cobicistat 150 mg) is a daily tablet to be taken with other antiretroviral...

Goldman Sachs reiterated its Neutral rating on Bristol Myers Squibb (NYSE: BMY) and AstraZeneca (NYSE: AZN). On Friday, AstraZeneca added 0.22% to its value to close the week at $49. Its shares lost all of Friday's gains in today's pre-market trading, however, falling 1.24% to $48.29. At the same...

Morgan Stanley upgraded its rating on Bristol Myers Squibb (NYSE: BMY) from Equal-weight to Overweight. At the same time, Morgan Stanley raised its price target on the company's stock from $28 to $34. In a research report published today, Morgan Stanley stressed the company's new product apixaban...

ZymoGenetics, Inc. (NASDAQ: ZGEN) has announced that the company will be acquired by Bristol Myers Squibb Company (NYSE: BMY) for $9.75/share (or ~$885M), and is believed by Oppenheimer to be attractively priced to investors at a ~77% premium to ZGEN's $5.51 closing price. Oppenheimer has suspended...

Bristol Myers Squibb Company (NYSE: BMY) reported 2Q results allude to potential for revenues in the future, according to Jefferies International, who believes that the shares are priced for perfect execution of the late-stage pipeline. Jefferies has raised the price target for BMY to $28.80 from $...